Search Result

Results for "

human FXIa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (6) Isotope-Labeled Compounds (1) Kallikrein (2) Thrombin (1)
By Research Areas:	Cardiovascular Disease (8) Metabolic Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137431

Asundexian 5 Publications Verification BAY-2433334	Factor Xa	Cardiovascular Disease
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a factor XIa (FXIa) inhibitor with a K_i of 0.7 nM against human *FXIa* and a K_i of 3 nM against rabbit *FXIa*. BMS-962212 blocks thrombosis while preserving normal hemostatic function. BMS-962212 is applicable to thrombosis-related research .

HY-150682

FXIa-IN-9	Factor Xa	Cardiovascular Disease
FXIa-IN-9 (compound 3f) is a potent and selective *FXIa* inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa K_i: 0.17 nM, rabbit FXIa K_i: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .

HY-163348

FXIIa-IN-4 1 Publications Verification	Factor Xa Thrombin	Cardiovascular Disease
FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC₅₀ of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and *FXIa*, respectively. FXIIa-IN-4 can be used for study of anticoagulant .

HY-145568

Feniralstat KVD-824	Kallikrein	Cardiovascular Disease Metabolic Disease
Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC₅₀ of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC₅₀>40 μM) .

HY-12631

BMS-654457	Factor Xa	Cardiovascular Disease
BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with K_is of 0.2 and 0.42 nM, respectively.

HY-145568A

Feniralstat hydrochloride	Kallikrein	Cardiovascular Disease Metabolic Disease
Feniralstat (compound 30) hydrochloride, a pyrazole derivative, is a potent kallikrein inhibitor with an IC₅₀ of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC₅₀>40 μM) .

HY-137431S

Asundexian-d3 BAY-2433334-d₃	Isotope-Labeled Compounds Factor Xa	Cardiovascular Disease
Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

Cat. No.	Product Name	Chemical Structure

HY-137431S

Asundexian-d3
Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.